Market Research Future (MRFR) has published a cooked research report on the “Global Chikungunya Vaccine Market” that contains the information from 2023-2030.

Chikungunya Vaccine Market Report Highlights

The Chikungunya Vaccine Market is expected to register a CAGR of 10.12% during the forecast period and is expected to hit USD 0.49 billion by 2030.

The chikungunya vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins.

The rising prevalence of chikungunya fever, increasing awareness about mosquito-transmitted infections and increasing government initiatives regarding prevention and control of chikungunya are the key factors fueling the market growth of the global chikungunya vaccine. Additionally, with the rising unmet needs for chikungunya treatment in developing and underdeveloped countries, the chikungunya vaccine market is expected to grow further in the coming years. However, stringent regulatory requirement might restrain the market's growth in the forecast period.

Segment Analysis

The global chikungunya vaccine market has been divided based on technology, age group and distribution channel.

The market, based on product, has been segmented into live-attenuated virus vaccines, inactivated viral vaccine, recombinant viral vaccines, chimeric-alphavirus candidates, and others.

Based on age group, the market of chikungunya vaccine has been divided into pediatric, adult, and geriatric.

Based on distribution channel, the market of chikungunya vaccine has been divided into hospital pharmacies, retail pharmacies, and other.

Key Players

Some of the key players operating in the chikungunya vaccine market are Takeda Pharmaceutical Company Limited (Japan), Valneva SE (France), Moderna, Inc. (China), Emergent BioSolutions Inc. (US), Bharat Biotech International Limited (India), Thermis Bioscience GmbH (Austria) and Auro Vaccine LLC. (US).

Regional Analysis

The global market of chikungunya vaccine, based on region, has been divided into the North America, Europe, Asia-Pacific, and the Rest of the World. The North America market is further divided into two parts: US and Canada. The Europe chikungunya vaccine market has been segmented into Germany, France, the UK, Italy, Spain, and the rest of Europe. The market of chikungunya vaccine in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. Rest of the World has been segmented into Middle East, Africa and Latin America.

The chikungunya vaccine market in the Rest of the World is growing dramatically due to interior government subsidiaries and inadequate healthcare system in the region. Furthermore, increasing prevalence of chikungunya viral infection will generate lucrative opportunities in the Rest of the World.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Chikungunya Vaccine Market Research Report

Key Findings of the Study

• The Americas region accounted for the largest share of the global market, owing to favourable reimbursement scenario, increasing government initiatives, and the presence of a large number of market players in the region.


• Based on technology, live-attenuated virus vaccines segment is expected to register the fastest growth at a CAGR of 11.52% during the forecast period.


• Based on age group, adult segment is expected to register the fastest growth at a CAGR of 10.46% during the forecast period


• Based on distribution channel, the hospital pharmacies segment held the fastest growth at a CAGR of 10.58% during the forecast period.